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LETTERS TO EDITOR 
case of Rabbit syndrome which occurred twice in 
two different admissions while she received 
highpotency antipsychotics for just one week, the 
response to shift on low potency and adding 
antiparkinson medicines was as good as in her 
case (Jain, 1993) 
I will like to know from the author, if 
extrpyramidal side effects also developed on the 
same day the perioral movements were noted ? 
Extrapyramidal side effects are usually visible after 
one or two days of antipsychotic administration. It 
looks that perioral movements were noted after a 
week of initiation of treatment and then only 
antiparkinson agents were started which mean that 
EPS also occurred on seventh day. 
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SERTRALINE AND BUSPIRONE IN 
ADOLESCENT DELUSIONAL BODY 
DYSMORPHIC DISORDER 
Sir, 
Delusional body dysmorphic disorder 
(BDD) is currently known to respond well to 
serotonin reuptake inhibitors (SRIs). However, 
patients with this disorder show a variable 
response to this class of drugs. We report a case 
of pimozide-resistant delusional BDD who failed 
a subsequent trial of clomipramine but ultimately 
responded to a combination of sertraline and 
buspirone. 
U.K., a 14-year-old girl, had been suffering 
for about 6 months from the belief that her eyes 
were becoming smaller and that her lower lip was 
smaller than her upper lip. The patient was deeply 
convinced about this belief, would spend an hour 
each day examining her face in front of a mirror 
and would apply lipstick to conceal the imagined 
defect. However, this behavior was never ego 
dystonic and she had no insight in to the 
psychological nature of her illness. She avoided 
meeting people, stopped going to the school, 
remained sad and expressed loss of interest, 
hopelessness, worthless and demonstrated 
vegetative signs suggestive of a mild depressive 
episode. During the entire illness, she never had 
obsessive-compulsive symptoms qualifying for a 
disorder. Family history was positive for paranoid 
schizophrenia in father but there was no history 
of any obsessive-compulsive spectrum disorder. 
The patient was diagnosed with delusional 
BDD and treated with pimozide up to 4 mg/day, 
which was discontinued after 5 months in view of 
severe extrapyramidal symptoms and no apparent 
improvement in her beliefs. Subsequently, she was 
treated with clomipramine up to 200 mg/day for 3 
months. Her depressive symptoms improved but 
her beliefs on the imagined defect persisted with 
the same intensity. Therefore, buspirone was 
added for augmentation. At a dose of 200 mg/day 
of clomipramine and 15 mg/day of buspirone, the 
patient had two episodes of generalized seizures. 
An EEG and cranial CT scan did not reveal any 
abnormality to suggest focal brain pathology. 
Clomipramine, due to its seizurogenic potential, 
was replaced with sertraline, which was increased 
to 150 mg/day while buspirone was continued at 
15 mg/day. Within two months of commencing 
this combination, the patient started showing 
improvement. Her frequency of mirror gazing 
decreased and she became more social. In 
another two months, she had rid herself of the 
delusional beliefs and was back to school. 
Currently, she is asymptomatic on this regimen 
for the past two years. 
To our knowledge, this is the first 
adolescent case of BDD where a combination of 
clomipramine and buspirone and sertraline and 
buspirone were tried in the same patient. Similar 
reports in adults have been documented in 
literature (Guggenheim, 2000) while the safety and 
efficacy of sertraline alone in adolescent BDD has 
been shown only anecdotally (Ei-khatib & Dickey, 
1995). In addition, this case offers other interesting 
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facets. BDD, whether delusional or non-
delusional, responds to antidepressants, 
particularly SRIs. A recent double-blind trial 
comparing clomipramine with desipramine 
demonstrated the efficacy of the former 
irrespective of whether the patients had insight or 
held their dysmorphic perception with delusional 
intensity (Hollander etal., 1999). Moreover, there 
are reports of cases resistant to pimozide, the 
traditional choice for delusional BDD, subsequently 
responding to SRIs, which also happened in this 
patient (Wada et al., 1999). Thus the emerging 
consensus is that SRIs may be considered as 
first line agents in the treatment of BDD (Phillips 
etal., 1998; Hollander etal., 1999). 
An intriguing observation in our case was 
the non-response to one SRI and a subsequent 
response to another. Such a preferential response 
to one SRI over another has been cited before 
(Dominguez & Puig, 1997). Hence, a failed trial of 
one SRI should not deter a clinician from trying a 
second SRI. Augmenting with buspirone 
represents another alternative. Finally, another 
finding of significant clinical importance is that the 
presence of obsessive-compulsive symptoms, 
syndromal or otherwise, in BDD are not a pre-
requisite for response to SRIs considering that 
these agents have additional anti-obsessive 
properties and that BDD is an obsessive-
compulsive spectrum disorder (Hollander et al., 
1999). This too was adequately demonstrated by 
this report. 
REFERENCES 
Dominguez,R.A. & Puig,A. (1997) 
Olfactory reference syndrome responds to 
clomipramine and not fluoxetine: a case report. 
Journal of Clinical Psychiatry, 58,497-498. 
EI-khatib,H.E. & Dickey.T.O. (1995) 
Sertraline for body dysmorphic disorder. Journal 
of American Academy of Child and Adolescent 
Psychiatry, 34,1404-1405. 
Guggenheim.F.G. (2000) Somatoform 
disorder. In : Comprehensive Textbook of 
Psychiatry, Vol, 1, Edn. 7, (Eds.) Sadock, B.J. & 
Sadock, V.A., pp 1529, Philadelphia . Lippincott, 
Williams & Wilkins. 
Hollander.E., Allen,A., Kwon.J., 
Aronowitz,B., Schmeidler,J., Wong.C. & 
Simeon,D. (1999) Clomipramine vs desipramine 
crossover trial in body dysmorphic disorder. 
Archives of General Psychiatry, 56,1033-1039. 
Phillips,K.A., Dwight.M.M. & 
McElroy,S.L. (1998) Efficacy and safety of 
fluvoxamine in body dysmorphic disorder. Journal 
of Clinical Psychiatry, 59,165-171. 
Wada.T, Kawakatsu.S., Nadaoka.T., 
Okuyama.N. & Otani.K. (1999) Clomipramine 
treatment of delusional disorder, somatic type. 
International Clinical Psychopharmacology, 14, 
181-183. 
HARPREETS. DUGGAL, DPM, Resident, SOUMYA BASU, 
DPM, Resident, SIDDHARTHA DUTTA, MD. DPM, Senior 
Resident, VINOD K. SINHA', MD, DPM, Associate 
Professor of Psychiatry, C.I.P., Kanke, Ranchi - 834006. 
(e-mail: bobduggal@yahoo.com) 
'Correspondence 
VENLAFAXINE - INDUCED ORTHOSTATIC 
HYPOTENSION 
Sir, 
Venlafaxine is a selective serotonin-
noradernaline reuptake inhibitor available in the 
Indian market in immediate and extended release 
(XR) preparations. Although dose-related 
hypertension is the commonly reported adverse 
effect of this drug with an incidence ranging form 
3 to 13 % depending on the dose (Beauclair et 
al., 2000), we describe a patient who developed 
unexpected orthostatic hypotension and had no 
underlying cardiac compromise 
P.T., a 46-year-old male diagnosed with 
treatment-resistant bipolar depression was started 
on venlafaxine-XR at a dose of 37.5 mg/day Then 
next dose hike was by 37.5 mg/day after four days 
with subsequent increase by 75 mg/day after a 
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